Across rheumatic diseases

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients

Clin Exp RheumatolPublished Prospective cohort study

Authors' conclusion

Forty-seven percent of initial non-responders seroconverted after two-dose revaccination but still had lower levels of SARS-CoV-2 antibodies compared with controls and blood donors. RD patients without a detectable serological response after the initial COVID-19 mRNA vaccine had a T-cell response similar to immunocompetent controls and blood donors.

Study context

Population
Patients with rheumatic diseases (RD) (SLE or RA) from a cohort vaccinated with the standard two-dose COVID-19 vaccinations; blood donors
Participants
17 / 29 / 32
Exposure
Initial vaccine non-responders vs responders and blood donors
  • Casesn = 17
  • Controlsn = 29reference
  • Blood donorsn = 32
Outcome
Antibody response (seroconversion; detectable neutralising antibodies) after COVID-19 mRNA revaccination (two doses)
Follow-up
Six weeks after completed revaccination
Methodological detailscase-control design, revaccination with two doses of COVID-19 mRNA vaccine
  • Case-control design
  • Revaccination with two doses of COVID-19 mRNA vaccine

Main finding

As reported in the abstract

Detectable neutralising antibodies after revaccination

Cases

47%

Observational data: associations, not effects.

Further findings

Measurable B-cells before revaccination

Measurable B-cells before revaccination among cases who seroconverted
50%

Antibody class switch in cases

Revaccination induced a decrease in IgM and increase in IgG in cases

T-cell responses before and after revaccination

No significant difference between the three groups

Original publication

Revaccination of patients with systemic lupus erythematosus or rheumatoid arthritis without an initial COVID-19 vaccine response elicits seroconversion in half of the patients. Clin Exp Rheumatol. Published 16 April 2023. doi:10.55563/clinexprheumatol/orpp04

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.